Publicações científicas

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Perez-Ruiz E (1,2,3,4,5), Minute L (1,2), Otano I (1,2), Alvarez M (1,2), Ochoa MC (1,2,6), Belsue V (1,2), de Andrea C (2,7), Rodriguez-Ruiz ME (1,3), Perez-Gracia JL (2,3,6), Marquez-Rodas I (6,8), Llacer C (9), Alvarez M (5,10,11), de Luque V (5,10), Molina C (1,2), Teijeira A (1,2,6), Berraondo P (12,13,14), Melero I (15,16,17,18,19).

(1) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
(2) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
(3) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
(4) Department of Oncology, Hospital Costa del Sol, Marbella, Spain.
(5) Instituto de Investigación Biomédica de Málaga (IBIMA), Hospitales Universitarios Regional y Virgen de la Victoria, Málaga, Spain.
(6) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
(7) Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.
(8) Department of Oncology, Hospital General Universitario Gregorio Marañon, Madrid, Spain.
(9) Department of Oncology, Hospital Universitario Virgen de la Victoria, Málaga, Spain.
(10) Laboratorio de Biología Molecular del Cáncer, Centro de Investigaciones Médico-Sanitarias (CIMES), Universidad de Málaga, Málaga, Spain.
(11) Department of Pathology, Faculty of Medicine, Universidad de Málaga, Málaga, Spain.
(12) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
(13) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
(14) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
(15) Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.
(16) Navarra Institute for Health Research (IDISNA), Pamplona, Spain.
(17) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
(18) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
(19) Department of Immunology and Immunotherapy, Clínica Universidad de Navarra, Pamplona, Spain.

Revisão:Nature

Data: 1/Mai/2019

Oncologia Médica Imunologia e Imunoterapia [ES]

Combined PD-1 and CTLA-4-targeted immunotherapy with nivolumab and ipilimumab is effective against melanoma, renal cell carcinoma and non-small-cell lung cancer1-3.

However, this comes at the cost of frequent, serious immune-related adverse events, necessitating a reduction in the recommended dose of ipilimumab that is given to patients4.

In mice, co-treatment with surrogate anti-PD-1 and anti-CTLA-4 monoclonal antibodies is effective in transplantable cancer models, but also exacerbates autoimmune colitis.

Here we show that treating mice with clinically available TNF inhibitors concomitantly with combined CTLA-4 and PD-1 immunotherapy ameliorates colitis and, in addition, improves anti-tumour efficacy. Notably, TNF is upregulated in the intestine of patients suffering from colitis after dual ipilimumab and nivolumab treatment.

We created a model in which Rag2-/-Il2rg-/- mice were adoptively transferred with human peripheral blood mononuclear cells, causing graft-versus-host disease that was further exacerbated by ipilimumab and nivolumab treatment. When human colon cancer cells were xenografted into these mice, prophylactic blockade of human TNF improved colitis and hepatitis in xenografted mice, and moreover, immunotherapeutic control of xenografted tumours was retained.

Our results provide clinically feasible strategies to dissociate efficacy and toxicity in the use of combined immune checkpoint blockade for cancer immunotherapy.

CITA DEL ARTÍCULO  Nature. 2019 May 1. doi: 10.1038/s41586-019-1162-y

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra